# Domvanalimab and Zimberelimab in Advanced Liver Cancers

Source: https://onco.cc/trials/nct05724563/  
OnCo record `nct05724563` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of zimberelimab and domvanalimab in gallbladder cancer and other biliary tract cancers, run by University of Texas Southwestern Medical Center, active and no longer recruiting.

## Summary

Domvanalimab and Zimberelimab in Advanced Liver Cancers is a phase 2 interventional study registered as NCT05724563 by University of Texas Southwestern Medical Center, with a registry enrolment figure of 58 participants, started 2023-06-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: Zimberelimab, Domvanalimab. Conditions listed: Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma. Gallbladder cancer is named in the registry entry: "1. Patient must have a histologically confirmed diagnosis consistent with HCC or bile duct cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancers); known fibrolamella". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05724563
- Phase: 2
- Setting: Phase II Basket Trial of Domvanalimab (AB154) and Zimberelimab (AB122) in Advanced Hepatobiliary Cancers
- Sponsor: University of Texas Southwestern Medical Center
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT05724563: https://clinicaltrials.gov/study/NCT05724563

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Domvanalimab](https://onco.cc/drugs/domvanalimab/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- key papers: [Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial](https://onco.cc/key-papers/paper-nct05724563-nat-commun-2025/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05724563.json